Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin H Cohen

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
The Oncologist|September 10, 2009
Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancerMartin H Cohen, Robert Justice, Richard Pazdur
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiformeMartin H Cohen, John R Johnson, Richard Pazdur
The Oncologist|October 29, 2002
Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug statusMartin H Cohen, Marie L Moses, Richard Pazdur
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approvalMartin H Cohen, John R Johnson, Richard Pazdur
The Oncologist|April 5, 2007
FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancerMartin H Cohen, Joe Gootenberg, Patricia Keegan, et al.
The Oncologist|December 15, 2010
Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC)Martin H Cohen, Patricia Cortazar, Robert Justice, et al.
The Oncologist|March 5, 2010
Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumorsMartin H Cohen, Patricia Cortazar, Robert Justice, et al.
The Oncologist|January 12, 2010
FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinomaJeff Summers, Martin H Cohen, Patricia Keegan, et al.
The Oncologist|July 3, 2007
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancerMartin H Cohen, Joe Gootenberg, Patricia Keegan, et al.
The Oncologist|February 6, 2009
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumorsMartin H Cohen, Ann Farrell, Robert Justice, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
The Oncologist|September 10, 2009
Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancerMartin H Cohen, Robert Justice, Richard Pazdur
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiformeMartin H Cohen, John R Johnson, Richard Pazdur
The Oncologist|October 29, 2002
Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug statusMartin H Cohen, Marie L Moses, Richard Pazdur
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approvalMartin H Cohen, John R Johnson, Richard Pazdur
The Oncologist|April 5, 2007
FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancerMartin H Cohen, Joe Gootenberg, Patricia Keegan, et al.
The Oncologist|December 15, 2010
Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC)Martin H Cohen, Patricia Cortazar, Robert Justice, et al.
The Oncologist|March 5, 2010
Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumorsMartin H Cohen, Patricia Cortazar, Robert Justice, et al.
The Oncologist|January 12, 2010
FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinomaJeff Summers, Martin H Cohen, Patricia Keegan, et al.
The Oncologist|July 3, 2007
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancerMartin H Cohen, Joe Gootenberg, Patricia Keegan, et al.
The Oncologist|February 6, 2009
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumorsMartin H Cohen, Ann Farrell, Robert Justice, et al.
Pageof 4